Treating Cannabis Dependence Improved Depression, Sleep, and Pain Even Without Full Abstinence

Cannabis dependence treatment gradually reduced depression, anxiety, insomnia, and pain symptoms regardless of whether patients received nabiximols or placebo, and even when complete abstinence was not achieved.

Montebello, Mark et al.·Drug and alcohol dependence·2022·Moderate EvidenceRandomized Controlled Trial
RTHC-04074Randomized Controlled TrialModerate Evidence2022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Randomized Controlled Trial
Evidence
Moderate Evidence
Sample
N=128

What This Study Found

Among participants with moderate-to-severe baseline scores, depression, anxiety, stress, and insomnia symptoms gradually decreased over 12 weeks of treatment. Pain decreased until week 12 but rebounded during the post-treatment period. Neither nabiximols vs placebo nor counseling sessions contributed significant explanatory power, suggesting treatment engagement itself drove improvement.

Key Numbers

128 participants; DASS-21, ISI, BPI at 5 timepoints; gradual symptom improvement over 12 weeks; pain rebounded post-treatment (weeks 12-24)

How They Did This

Secondary analysis of a 12-week double-blind placebo-controlled trial of nabiximols in 128 cannabis-dependent participants. DASS-21, Insomnia Severity Index, and Brief Pain Inventory measured at weeks 0, 4, 8, 12, and 24.

Why This Research Matters

Many cannabis-dependent individuals also struggle with mood, sleep, and pain problems. This study shows that reducing cannabis use improves these comorbidities even without achieving full abstinence.

The Bigger Picture

The finding that treatment engagement matters more than the specific medication challenges the all-or-nothing model of addiction treatment. Partial reduction in cannabis use still produced meaningful improvements.

What This Study Doesn't Tell Us

Secondary analysis. Cannot determine if symptom improvement caused reduced cannabis use or vice versa. Pain rebound post-treatment suggests ongoing pain management is needed.

Questions This Raises

  • ?Would longer treatment duration prevent the post-treatment pain rebound?
  • ?Can partial cannabis reduction be formalized as a treatment goal rather than requiring full abstinence?

Trust & Context

Key Stat:
Symptoms improved even without full abstinence
Evidence Grade:
Secondary analysis of a well-designed RCT, but the lack of medication effect limits causal conclusions about specific treatment mechanisms.
Study Age:
Published in 2022
Original Title:
Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.
Published In:
Drug and alcohol dependence, 234, 109388 (2022)
Database ID:
RTHC-04074

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled TrialGold standard for testing treatments
This study
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal Study

Participants are randomly assigned to treatment or placebo groups to test cause and effect.

What do these levels mean? →

Frequently Asked Questions

Does quitting cannabis improve depression and sleep?

In this trial, reducing cannabis use (even without complete abstinence) was associated with gradual improvements in depression, anxiety, stress, and insomnia over 12 weeks of treatment.

Did nabiximols help with comorbid symptoms?

Neither nabiximols specifically nor the number of counseling sessions predicted symptom improvement. The key factor appeared to be treatment engagement and reduced cannabis use overall.

Read More on RethinkTHC

Cite This Study

RTHC-04074·https://rethinkthc.com/research/RTHC-04074

APA

Montebello, Mark; Jefferies, Meryem; Mills, Llewellyn; Bruno, Raimondo; Copeland, Jan; McGregor, Iain; Rivas, Consuelo; Jackson, Melissa A; Silsbury, Catherine; Dunlop, Adrian; Lintzeris, Nicholas. (2022). Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.. Drug and alcohol dependence, 234, 109388. https://doi.org/10.1016/j.drugalcdep.2022.109388

MLA

Montebello, Mark, et al. "Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.." Drug and alcohol dependence, 2022. https://doi.org/10.1016/j.drugalcdep.2022.109388

RethinkTHC

RethinkTHC Research Database. "Mood, sleep and pain comorbidity outcomes in cannabis depend..." RTHC-04074. Retrieved from https://rethinkthc.com/research/montebello-2022-mood-sleep-and-pain

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.